G. Bodoky

33.2k total citations · 9 hit papers
165 papers, 14.5k citations indexed

About

G. Bodoky is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, G. Bodoky has authored 165 papers receiving a total of 14.5k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 75 papers in Pulmonary and Respiratory Medicine and 31 papers in Surgery. Recurrent topics in G. Bodoky's work include Colorectal Cancer Treatments and Studies (89 papers), Gastric Cancer Management and Outcomes (47 papers) and Pancreatic and Hepatic Oncology Research (34 papers). G. Bodoky is often cited by papers focused on Colorectal Cancer Treatments and Studies (89 papers), Gastric Cancer Management and Outcomes (47 papers) and Pancreatic and Hepatic Oncology Research (34 papers). G. Bodoky collaborates with scholars based in Hungary, United States and Spain. G. Bodoky's co-authors include Eric Van Cutsem, David Cunningham, Philippe Rougier, Paul Ruff, Sabine Tejpar, Jaffer A. Ajani, Claus-Henning Köhne, Christopher Stroh, Gunnar Folprecht and Tamás Pintér and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

G. Bodoky

160 papers receiving 14.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, G. Bodoky et al. profile →
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

2014 1.7k citations H. Wilke, Kei Muro et al. The Lancet Oncology profile →
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

2010 1.4k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

2009 893 citations Arnaud Roth, Dirk Klingbiel et al. Journal of Clinical Oncology profile →
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology

2006 653 citations G. Bodoky et al. profile →
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

2015 652 citations Josep Tabernero, Takayuki Yoshino et al. The Lancet Oncology profile →
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

2013 621 citations Yoon‐Koo Kang, Hyun Cheol Chung et al. The Lancet Oncology profile →
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

2010 425 citations Jaffer A. Ajani, W. Rodriguez et al. Journal of Clinical Oncology profile →
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

2017 391 citations Peter Thuss‐Patience, Manish A. Shah et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by G. Bodoky

Since Specialization

Citations

This map shows the geographic impact of G. Bodoky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Bodoky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Bodoky more than expected).

Fields of papers citing papers by G. Bodoky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Bodoky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Bodoky. The network helps show where G. Bodoky may publish in the future.

Co-authorship network of co-authors of G. Bodoky

This figure shows the co-authorship network connecting the top 25 collaborators of G. Bodoky. A scholar is included among the top collaborators of G. Bodoky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Bodoky. G. Bodoky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rationale and Design of the PROMETCO Study: A Real-World, Prospective, Longitudinal Cohort on the Continuum of Care of Metastatic Colorectal Cancer From a Clinical and Patient Perspective 2022 ·Future Oncology ·Miriam Koopman, Carmine Pinto, G. Bodoky, Rocio García‐Carbonero, Francisca M. Marti, Jean‐Baptiste Bachet	3
2	Medical Oncology Workload in Europe: One Continent, Several Worlds 2019 ·Clinical Oncology ·Boštjan Šeruga, Richard Sullivan, Adam Fundytus, Wilma M. Hopman, Alberto Ocaña, Johnathan Joffe, G. Bodoky, C. Le Tourneau, Verna Vanderpuye, Gilberto Lopes, Nazik Hammad, Manju Sengar, Michael Brundage, Christopher M. Booth	14
3	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer 2017 ·Molecular Cancer Therapeutics ·Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Jaffer A. Ajani, Jiří Tomášek, Howard Safran, Kumari Chandrawansa, Yanzhi Hsu, Michael Heathman, Azhar Khan, Lan Ni, Allen S. Melemed, Ling Gao, David Ferry, Charles S. Fuchs	34
4	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study breakdown → 2017 ·The Lancet Oncology ·Peter Thuss‐Patience, Manish A. Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A. Ajani, Hugo R. Castro, Wasat Mansoor, Hyun Cheol Chung, G. Bodoky, Kohei Shitara, Gail D. Lewis Phillips, T. van der Horst, (unknown), Betsy Althaus, Yoon‐Koo Kang	391
5	Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment 2017 ·Annals of Oncology ·Jordi Bruix, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, Jean–Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, (unknown), Annette Baumhauer, Gerold Meinhardt, Guohong Han	6
6	Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08) 2017 ·European Journal of Cancer ·Roger von Moos, Dieter Koeberle, (unknown), Stefanie Hayoz, (unknown), Arnaud Roth, G. Bodoky, Panagiotis Samaras, Martin D. Berger, Daniel Rauch, Piercarlo Saletti, Ludwig Plaßwilm, Daniel R. Zwahlen, Urs R. Meier, (unknown), Paola Izzo, Dirk Klingbiel, Daniela Bärtschi, Kathrin Zaugg	20
7	O-007 Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study 2016 ·Annals of Oncology ·Eric Van Cutsem, Kei Muro, David Cunningham, G. Bodoky, Alberto Sobrero, Stefano Cascinu, Jaffer A. Ajani, Atsushi Ohtsu, (unknown), S-E. Al-Batran, Zev A. Wainberg, Rebecca R. Hozak, Haojun Ouyang, Symantha Melemed, D. Ferry, H. Wilke	5
8	Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial 2016 ·Annals of Oncology ·Jordi Bruix, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, J.-P. Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, (unknown), Annette Baumhauer, Gudrun Meinhardt, Guohong Han	8
9	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma 2016 ·Annals of Oncology ·Salah‐Eddin Al‐Batran, Eric Van Cutsem, Sang Cheul Oh, G. Bodoky, Yoshifumi Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, T.-Y. Kim, David Cunningham, P. Rougier, Kei Muro, Astra M. Liepa, Kumari Chandrawansa, Michael Emig, Atsushi Ohtsu, H. Wilke	55
10	Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer 2016 ·Annals of Oncology ·Sara Lonardi, (unknown), Takayuki Yoshino, Radka Obermannová, G. Bodoky, Jana Prausová, Rocio García‐Carbonero, T-E. Ciuleanu, Pilar García‐Alfonso, David C. Portnoy, Eric Van Cutsem, Kentaro Yamazaki, P. Clingan, Jonathan Polikoff, Ling Gao, Lifen Yang, Sanders Chang, D. Ferry, Federico Nasroulah, Josep Tabernero	1
11	Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) 2016 ·Annals of Oncology ·Dieter Koeberle, Jean‐François Dufour, Gyula Demeter, (unknown), Karin Ribi, Panagiotis Samaras, Piercarlo Saletti, A. Roth, Daniel Horber, M. Buehlmann, Dorothea Wagner, Michael Montemurro, Gábor Lakatos, Jonas Feilchenfeldt, Markus Peck‐Radosavljevic, Daniel Rauch, (unknown), G. Bodoky	102
12	Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab Plus Paclitaxel vs Placebo Plus Paclitaxel Patients with Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma – Patient-Reported Outcomes and Performance Status 2014 ·Annals of Oncology ·S. Al-Batran, Eric Van Cutsem, (unknown), G. Bodoky, Yoshifumi Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae Yong Kim, David Cunningham, P. Rougier, Kei Muro, (unknown), (unknown), Michael Emig, Atsushi Ohtsu, H. Wilke	1
13	Clinical Benefit Response in Pancreatic Cancer Trials Revisited 2014 ·Oncology Research and Treatment ·Jürg Bernhard, Daniel Dietrich, Bengt Glimelius, G. Bodoky, Werner Scheithauer, Richard Herrmann	9
14	Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC) 2013 ·Annals of Oncology ·Kelly S. Oliner, Jean‐Yves Douillard, Salvatore Siena, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, (unknown), Martin Šmakal, Richard T. Williams, Alan Rong, Jeffrey S. Wiezorek, Roger Sidhu, Scott D. Patterson	2
15	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III) 2012 ·Journal of Clinical Oncology ·Hans‐Joachim Schmoll, David Cunningham, Alberto Sobrero, Christos S. Karapetis, Philippe Rougier, Sheryl Koski, Ilona Kocáková, Igor Bondarenko, G. Bodoky, Paul N. Mainwaring, Ramón Salazar, Peter Barker, Bijoyesh Mookerjee, Jane Robertson, Eric Van Cutsem	163
16	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial breakdown → 2010 ·Journal of Clinical Oncology ·Jaffer A. Ajani, W. Rodriguez, G. Bodoky, Vladimir Moiseyenko, Mikhail Lichinitser, В. А. Горбунова, Ihor Vynnychenko, August Garin, István Láng, S. Falcon	425
17	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study breakdown → 2010 ·Journal of Clinical Oncology ·Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean‐Luc Canon, M. Rother, Kelly S. Oliner, Michael Wolf, Jennifer Gansert	1351
18	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab 2007 ·British Journal of Cancer ·Salvatore Siena, Marc Peeters, Eric Van Cutsem, Yves Humblet, Pierfranco Conté, Emilio Bajetta, Danila Comandini, G. Bodoky, Guy van Hazel, (unknown), Michael Wolf, Giovanna Devercelli, Michael Woolley, (unknown)	65
19	Ileocolic Anastomotic Ulcer after Surgery in Adulthood: Case Report and Review of the Literature 2004 ·Zeitschrift für Gastroenterologie ·(unknown), G. Bodoky, Zsuzsanna Szabó, (unknown), Zoltán Varga, (unknown)	3
20	Effect of enteral nutrition on exocrine pancreatic function 1991 ·The American Journal of Surgery ·G. Bodoky, László Harsányi, Tibor Tihanyi, L Flautner, Ákos Pap	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact